This past weekend at #AHSAM was incredible. Thanks to the entire scientific and medical community for all the work that you do to help #migraine patients.

Let’s play a little game. Let’s say that you’re the CSO at a cancer pharma company, and you have to choose a target to go after. Here’s a gene – high expression is associated with poor prognosis in brain cancer. Looks like a good candidate for an inhibitor right?

Our #NGLY1-CDDG drug repurposing paper has been accepted by DMM Journal! Excited for the therapeutic potential of our clinical candidate aripiprazole/Abilify, which we believe could treat the complex movement disorder that is a defining clinical feature of #NGLY1 Deficiency.

#ICYMI: We recently closed $102 million in #SeriesC financing. Read more here about our investors, partners and plans to become a fully integrated #biotech company. See more: bit.ly/2TLoTmp #biotech #targetedproteindegradation

There's hope that vaccines will be our save us from COVID-19. Take a look at my recent piece in The Atlantic (with Graeme Wood). theatlantic.com/ideas/archive/… Many thanks to Graeme Wood for bringing me in on this exciting article.

STUDY MAY PROCEED!!!

Elon Musk challenged Vladimir Putin to “single combat," with the “stakes” being Ukraine.

Taking "induction of proximity" to a new level, Arena BioWorks, a Biomedical Research Institute that just launched in Boston, is bringing academic inquiry and biotech creation under one roof. prnewswire.com/news-releases/…

Interesting conceptual view on catalytic protein inhibitors by Thomas Kodadek Angewandte Chemie onlinelibrary.wiley.com/doi/10.1002/an…

Extracellular targeted protein degrader removes antibodies in first test in humans bit.ly/3RwQBAE Find out about the latest advances in broadening the concept of targeted protein degradation to encompass extracellular proteins in this news article published today

For readers interested in approaches for extracellular targeted protein degradation, here's a comprehensive review bit.ly/489BXVZ rdcu.be/dLaX8

We’re hiring a tenure-track professor (any level) to teach courses and develop research programs in experimental physical, theoretical, or organic chemistry, starting 8/1/25. Apply by 9/30/24 to be considered for the first round of interviews. apply.interfolio.com/150561

We really enjoyed putting this accounts paper together , placing our contributions to the covalent stabilization of ternary complexes in the context of induced proximity pubs.acs.org/doi/abs/10.102…

Time to revisit this Paul Noth gem.

"All authors contributed equally" Authors:

Here's the thing. We have **NO IDEA** how to pick good graduate students. I served on admission committees for 10+ years, and chaired a few, and what I learned is that all the spreadsheets of grades and test scores and recommendations and essays and publications and interview

In addition to wildcard government changes, 5 things I'm watching this year: 1. Tech: Degraders 2. Tech: Masked bi-specifics 3. Tech: Cell Tx in autoimmune rises or falls? 4. Obesity: Will something (amylin) improve on GLP tolerability and longevity of use? 5. China competition

Ari Fleischer You know perfectly well that this is not a handout. It is grant funding from NIH, NSF, DOE etc. Those grants have provided fundamental discoveries that have improved health, living standards, and created jobs. E.g., the two most widely prescribed HIV drugs were discovered in

OH MY FUCKING GOD. YOUR ENTIRE BUSINESS RUNS ON MASSIVE AMOUNTS OF UNPAID LABOUR YOU HYPOCRITICAL SHITGIBBONS.

Such a compelling story. Outstanding work. Off topic: has Brad Loncar ever asked a bad question? So good at what he does.